Potential Uses of Interleukin 2 in Cancer Therapy
- 1 September 1986
- journal article
- research article
- Published by Elsevier in Immunobiology
- Vol. 172 (3-5), 365-382
- https://doi.org/10.1016/s0171-2985(86)80118-8
Abstract
No abstract availableThis publication has 39 references indexed in Scilit:
- Antigen-driven long term-cultured T cells proliferate in vivo, distribute widely, mediate specific tumor therapy, and persist long-term as functional memory T cells.The Journal of Experimental Medicine, 1986
- Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic CancerNew England Journal of Medicine, 1985
- Lymphokine-activated killer (LAK) cells. Analysis of factors relevant to the immunotherapy of human cancerCancer, 1985
- Adoptive Immunotherapy of Established Pulmonary Metastases with LAK Cells and Recombinant Interleukin-2Science, 1984
- Generation of nonspecific murine cytotoxic T cells in vitro by purified human interleukin 2Cellular Immunology, 1984
- Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2.The Journal of Experimental Medicine, 1984
- Studies on chemically induced rat tumors. II. Partial protection against syngeneic lethal tumors by cloned syngeneic cytotoxic T lymphocytesInternational Journal of Cancer, 1983
- Augmentation of the anti-tumor therapeutic efficacy of long-term cultured T lymphocytes by in vivo administration of purified interleukin 2.The Journal of Experimental Medicine, 1982
- Treatment of B-Cell Lymphoma with Monoclonal Anti-Idiotype AntibodyNew England Journal of Medicine, 1982
- Genetic Control of the Immune Response to Thy‐1 Antigens1Immunological Reviews, 1978